New Thalidomide Derivative with An Anti-Migrative and Anti-Proliferative Effects on Lewis Lung Carcinoma Cell

Due to the crucial demand for novel chemotherapeutic agents, for the first time it was reported in the current study the potential anticancer effects of a new thalidomide derivative against Lewis lung carcinoma (LLC) cell line. The potential anticancer activities of the analog were detected through determination the anti-proliferation, anti-migration, and anti-invasive activities using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT), wound healing, and Matrigel invasion assays, respectively. In addition, the effect on the gene status of the pathway of PI3K/Akt/mTOR in LLC was determined. Moreover, the mRNA expression levels of transforming growth factor beta 1 (TGF-beta 1), Snail, Slug, and matrix metalloproteinase-2 (MMP-2) were measured through Quantitative Real-time RT-PCR. Results revealed significant inhibition of thalidomide analog on the proliferation, migration, and invasion of LLC cells was observed, compared to thalidomide drug. Furthermore, the analog inhibited the gene expression of PI3K, Akt, and mTOR. This chemical also decreased extensively the TGF-beta 1 mRNA expression, Snail, Slug, and MMP-2 than thalidomide. Taken together, our findings showed that the new thalidomide analog might be a potential anticancer candidate more than thalidomide drug against LLC cells through inhibition of cell proliferation, migration, and invasion.